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The effect of the TM6SF2 E167K 
variant on liver steatosis and 
fibrosis in patients with chronic 
hepatitis C: a meta-analysis
Zhengtao Liu1,2, Shuping Que3, Lin Zhou2, Shusen Zheng2, Stefano Romeo4,5,  
Adil Mardinoglu  1,6 & Luca Valenti  7,8
The impact of Transmembrane 6 superfamily member 2 (TM6SF2) E167K variant, which causes 
hepatocellular fat retention by altering lipoprotein secretion, on liver damage and metabolic traits 
in chronic hepatitis C patients is still debated. We performed a systematic review and meta-analysis 
to clarify this relationship. Four studies with a total of 4325 patients were included. The risk of 
histologically-determined advanced steatosis, fibrosis, and cirrhosis (but not of severe inflammation) 
were increased in carriers of the TM6SF2 variant (P < 0.05). Unlike the inconsistent association with 
steatosis severity, due to the confounding effect of infection by the genotype-3 hepatitis C virus, the 
TM6SF2 variant was robustly associated with advanced fibrosis (OR = 1.07; 95% confidence interval 
[CI] = 1.01–1.14) and in particular with cirrhosis (OR = 2.05; 95% CI = 1.39–3.02). Regarding metabolic 
features, individuals positive for the TM6SF2 variant exhibited 5.8–12.0% lower levels of circulating 
triglycerides and non-HDL cholesterol (P < 0.05). Carriers of the variant were leaner, but there was high 
heterogeneity across studies (I2 = 97.2%). No significant association was observed between the TM6SF2 
variant and insulin resistance or hepatitis C viral load (both P > 0.05). In conclusion, the TM6SF2 E167K 
variant promotes the development of steatosis, fibrosis and cirrhosis in patients with chronic hepatitis 
C. Conversely, this variant reduces circulating atherogenic lipid fractions.
Despite the advent of highly effective direct antiviral agents1, hepatitis C virus (HCV) infection still affects more 
than 130 million individuals worldwide and accounts for a large proportion of liver-related mortality. However, in 
patients with chronic hepatitis C (CHC) there is a wide inter-individual variability in the susceptibility to develop 
of progressive liver disease, which may lead to cirrhosis and hepatocellular carcinoma2.
Steatosis, defined as hepatocellular fat accumulation exceeding 5% of liver weight, is a typical histological fea-
ture of CHC, which is associated with higher likelihood of progression of liver damage and fibrosis3, 4. Both viral 
factors, e.g., infection by HCV-genotype 3 (G3), and host factors, including overweight, type 2 diabetes and at risk 
alcohol intake, contribute to the development of steatosis in patients with CHC5–7.
Inherited host factors modify the susceptibility to the development of steatosis and liver damage progression 
in patients with CHC. We and others have previously shown that the I148M variant of the Patatin-like phos-
pholipase domain-containing 3 (PNPLA3) gene, the major common genetic determinant of hepatic fat content, 
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influences the development of steatosis, and the progression towards advanced fibrosis and hepatocellular carci-
noma in patients with CHC8–11.
Recently, the rs58542926 C > T genetic variant of the Transmembrane 6 superfamily member 2 gene (TM6SF2), 
which encodes for the E167K aminoacidic substitution, has been identified as a determinant of hepatic fat content 
and lower serum lipoproteins levels12, 13. This mechanism is related to the inhibition of lipidation of very-low 
density lipoproteins (VLDLs)14, which cause lipid compartmentalization within hepatocytes12, 13, 15, 16, thereby 
triggering steatohepatitis and fibrogenesis16–18.
Subsequent studies conducted in patients with CHC suggested that the E167K variant is also associated with 
steatosis19–21 and fibrosis development20, 21 in this specific population. However, in the CHC setting the associa-
tion with fibrosis development remains controversial19, 22, and the overall evidence does not support an associa-
tion of the E167K variant with liver enzymes, and index of hepatic inflammation23.
Therefore, this study investigated the association of the TM6SF2 E167K variant with histological liver dam-
age (i.e., steatosis, hepatic inflammation, and fibrosis) in patients with CHC by performing a systematic review 
and meta-analysis of the available literature. As secondary outcomes, we also evaluated the impact of the E167K 
variant on circulating lipids, other metabolic traits and their interaction with TM6SF2-histological damage 
associations.
Results
Literature retrieval. The initial literature search yielded 19 potential references after excluding 14 duplicates 
across three databases. The manual search did not identify any additional studies. Three studies were omitted 
based on their titles and abstracts, and 12 studies were excluded because of specifically listed reasons. Finally, 
four eligible studies were selected with high inter-author consistency (Cohen’s kappa = 0.69). The flow chart is 
presented in Fig. 1.
Study characteristics and quality assessment. The major characteristics of the four studies included in 
the analyses are presented in Table 1. Overall, 4325 patients with CHC were enrolled in the analysis. The number 
of enrolled patients was heterogeneous, varying from 148 to 2023 (equal to 3.4% and 46.8% of all patients, respec-
tively). All participants were Caucasian, with a mean age that ranged between 44 and 58 years old. Nearly all of 
the studies selected patients naïve for anti-HCV therapy. The distribution of HCV genotypes was uneven across 
the studies (P < 0.05). All of the studies applied TaqMan assays for genotyping, and the genotype distribution 
of the TM6SF2 E167K variant did not violate the Hardy-Weinberg equilibrium (P > 0.05), with carriage of the 
E167K variant (EK + KK genotypes) frequency ranging from 6.3 to 12.2%. With respect to the liver biopsy results, 
four studies evaluated the extent of histological steatosis/fibrosis, and three evaluated the extent of inflammation 
(Table 2). Histological features were classified according to different criteria24–27 (Table S3).
Regarding study quality, three of the four studies had defects in the methods and results sections, according to 
criteria of the STREGA statement (Table S2).
TM6SF2 variant and steatosis severity in patients with CHC. The TM6SF2 E167K variant showed 
a comprehensive impact on steatosis severity. Carriage of the TM6SF2 variant had a more prominent effect on 
Figure 1. Flow chart of selected studies for meta-analysis.
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the risk of advanced steatosis in non-HCV-G3 infected patients (OR 1.12 vs. 1.05, P < 0.05, Fig. 2). Interestingly, 
we found that the TM6SF2 genotype distribution was unequal in patients with CHC stratified by HCV genotype 
(P < 0.05). Compared with HCV-G3 patients and healthy controls, non-HCV-G3 patients had a significantly 
lower prevalence of E167K variant carriers (15.6% and 13.6% vs. 9.2%, respectively; P < 0.01, Figure S1).
When steatosis was treated as a dichotomous variable, it was robustly associated with the TM6SF2 variant 
across the whole CHC population (pooled adjusted OR = 1.55, 95% CI = 1.23–1.94), with low inter-subgroup het-
erogeneity (I2 = 0%, P = 0.55, Figure S2A). An increased prevalence of severe steatosis (≥S3) was also observed 
in carriers of the E167K variant (12.6% vs. 7.2%, respectively; pooled adjusted OR = 2.19, 95% CI = 1.48–3.24; 
Figure S2B).
An additional subgroup analysis revealed that certain demographic characteristics such as younger age, male 
gender, higher BMI and a larger sample size of the study were associated with a reduced impact of the TM6SF2 
variant on steatosis severity (P < 0.05, Table 3 left panel), which is consistent with the results of the sensitivity 
analysis (Figure S3A). A cumulative meta-analysis also found decreased but stable effects of the TM6SF2 variant 
on steatosis as the sample sizes increased (Figure S4A).
TM6SF2 variant and inflammation activity in patients with CHC. Less information was available 
in the literature regarding the association between TM6SF2 variation and hepatic inflammation (Table 2). For 
continuous comparisons, the pooled risk on inflammation progression was 1.14, but the 95% CI ranged across 1 
(Figure S5A). Regarding the dichotomous comparison, the TM6SF2 variant was not associated with more severe 
inflammatory activity (Fig. 3 and Figure S5B). Importantly, overall study results were uncertain with significant 
inconsistency (I2 ranged from 42.6 to 79.7%). Only Milano M. et al., detected a positive association between the 
TM6SF2 E167K variant and severe inflammation. However, a sensitivity analysis did not reveal any specific study 
as a potential confounder that influenced the overall results (Figure S3B). These data suggest that the TM6SF2 
variant had no to little effect on the development of hepatic inflammation in patients with CHC.
TM6SF2 variant and fibrosis in patients with CHC. The TM6SF2 variant showed a robust association 
with fibrosis development in patients with CHC. For continuous comparisons, the presence of E167K increased 
the risk of advanced fibrosis by 7% (95% CI = 1.01–1.14, Fig. 4A), with low heterogeneity (I2 = 24.5%, P = 0.266; 
Fig. 4A). Regarding the dichotomous comparisons, the TM6SF2 variant was also associated with significant fibro-
sis (pooled OR = 1.34, 95% CI = 1.08–1.67) without obvious discrepancy (I2 = 0%, P = 0.779), despite the classifi-
cation using diverse scoring systems (Fig. 4B). Importantly, the prevalence of cirrhosis was higher among E167K 
carriers than non-carriers (16.0 vs. 10.8%, respectively). Indeed, after adjusting for potential covariates (Table 2), 
the TM6SF2 variant was significantly associated with an approximately two-fold higher risk of cirrhosis (pooled 
OR = 2.05, 95% CI = 1.39–3.02; Figure S6). In contrast to what was observed for steatosis, a subgroup analysis 
did not demonstrate any confounds with obvious interference on the TM6SF2-fibrosis association (all P > 0.05, 
Table 3 right panel). A sensitivity analysis did not find any specific study that significantly influenced the pooled 
OR of significant fibrosis (Figure S3C). The results of the cumulative meta-analysis found that the genetic effects 
of the TM6SF2 variant on fibrosis severity became significant and more stable after the results from the larger 
sample of Eslam et al. were included (Figure S4B).
First author, year, 
study [Reference 
Values for Arterial 
Stiffness, #2467]
Ethnicity, 
Country
Gender N, 
(women%)
Age (yr, 
mean ± SD)
BMI (kg/m2, 
mean ± SD)
Cohort 
characteristics Study design HCV genotype:(N) Genotyping
TM6SF2 
E167K 
genotype 
(EE + KK%)
P-value 
for HWE
N. Coppola19 Caucasian, Italy 148,(45.2)
EE: 51 ± 12 
EK + KK: 
53 ± 14
EE: 26 ± 0.4 
EK + KK: 
24 ± 1.2
1. CHC patients; 
2. no other 
liver disease 
and steatogenic 
medication; 3. 
before antiviral 
treatment
Hospital 
based cross-
sectional
G1/G2/G3/G4: 
EE:87/28/13/2 
EK + KK:14/2/2/0
TaqMan
EE/EK/KK: 
130/18/0 
(12.2%)
0.43
M. Milano, 2015, 
Milan cohort20
Caucasian, 
Italy 815,(43.6)
EE: 58 ± 13 
EK + KK: 
57 ± 13
EE: 24.8 ± 3.5 
EK + KK: 
24.5 ± 2.7
1. CHC patients; 
2. no other liver 
disease; 3. before 
antiviral therapy
Hospital 
based cross-
sectional
G1/G2/G3/G4: 
EE:430/202/45/69 
EK + KK:35/10/20/4
TaqMan EE/EK + KK: 746/69 (8.5%) 0.37
M. Milano, 2015, 
validation cohort22
Caucasian, 
Swiss/ 
Germany
645,(44.3)
EE: 53 ± 12 
EK + KK: 
50 ± 11
NA
1. CHC patients; 
2. no other liver 
disease 3. before 
antiviral therapy
Hospital 
based cross-
sectional
NA TaqMan
EE/EK + KK: 
550/95 
(14.7%)
>0.05
S. Petta, 201522 Caucasian, Italy 694,(45.7)
EE: 54 ± 12 
EK + KK: 
53 ± 12
EE: 26.6 ± 3.6 
EK + KK: 
25.7 ± 2.9
1. CHC patients, 
2. no other liver 
disease
Hospital 
based cross-
sectional
G1: 694 EE:650 
EK + KK:44 TaqMan
EE/EK + KK: 
650/44 (6.3%) 0.74
M. Eslam, 201621
Caucasian, 
Australia/
UK/Spain/
Italy/
Germany
2023,(37.7)
EE: 45 ± 11 
EK: 44 ± 11 
KK: 45 ± 7
EE: 26.5 ± 4.9 
EK + KK: 
25.8 ± 4.3
1. CHC patients; 
2. no other liver 
disease 3. before 
antiviral therapy
Hospital 
based cross-
sectional
G1/G2/G3/G4: 
1335/202/445/41 TaqMan
EE/EK/KK: 
1778/235/10 
(12.1%)
0.55
Table 1. Characteristics of the studies selected for meta-analysis.
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TM6SF2 variant and circulating lipids in patients with CHC. All of the considered studies reported 
the effect of the TM6SF2 E167K variant on circulating lipids. The E167K variant was associated with decreased 
levels of circulating lipids in patients with CHC (Fig. 5). Quantitative comparisons revealed that E167K car-
riers had approximately 12.0% lower TG levels (1.03 ± 0.52 vs. 1.17 ± 0.67 mmol/L; pooled SMD = 0.20, 95% 
CI = 0.08–0.32 mmol/L, I2 = 0%, Fig. 5A), and 6.1% lower TC levels (4.28 ± 0.93 vs. 4.56 ± 1.52 mmol/L, pooled 
SMD = 0.18, 95% CI = 0.07–0.29 mmol/L, I2 = 0%; Fig. 5B) than non-carriers. LDL-C but not HDL-C was lower 
in carriers of the E167K variant (pooled SMD = 0.16, 95% CI = 0.03–0.28 mmol/L). However, this latter analysis 
First author, publication 
year, study, [Reference 
Values for Arterial Stiffness, 
#2467] Subgroup
Histological 
feature
Scoring system 
[Reference Values 
for Arterial 
Stiffness, #2467] Numbera: (N) Comparisonb Statistics OR(95% CI) P-value Adjustment
N. Coppola, 201519 None Steatosis NAS24 S0/S1/S2/S3: EE:45/69/6/10 EK + KK:2/10/2/4 S2 + S3 vs. S0 + S1 Chi-square 3.56 (1.17–10.8) 0.02 None
None Fibrosis Ishak25
F0/F1/F2/F3/F4/F5/
F6: EE:3/40/35/29/14/7/2 
EK + KK:2/5/3/3/3/1/1
F4-F6 vs. F0-F3 Chi-square 1.79 (0.58–5.51) 0.31 None
M. Milano, 2015, Milan 
cohort20 None Steatosis Ishak
25 S0/S1/S2/S3: EE:240/383/87/36 
EK + KK:15/36/11/7 S2 + S3 vs. S0 + S1 Chi-square 1.79 (1.01–3.16) 0.04 None
Genotype3 
CHC Steatosis Ishak
25 NA S(X + 1) vs. S(X)c Ordinal regression 1.23 (0.60–2.52) 0.58
Age, gender, BMI, HCV 
G3,diabetes, alcohol 
intake, PNPLA3 I148M
Genotype 
(1 + 2 + 4) 
CHC
Steatosis Ishak25 NA S(X + 1) vs. S(X) Ordinal regression 1.33 (1.03–1.72) 0.03
Age, gender, BMI, 
diabetes, alcohol intake, 
PNPLA3 I148M
None Inflamma tion Ishak25
G0-G2/G3-G4/G5-G6/ G7-G8/
G9-G10/G11-G12 /G13-G18: 
EE:26/105/262/209/92/ 39/13 
EK + KK: 0/17/26/13/5/4/4
G(X + 1) vs. G(X)d Ordinal regression 1.27 (1.02–2.59) 0.04
Age, gender, BMI, HCV 
G3, diabetes, alcohol 
intake, ancestry, PNPLA3 
I148M
None Fibrosis Ishak25 F0/F1/F2/F3/F4/F5/F6: EE:12/118/201/154/71/60/130 F6 vs. F1-F5
Logistic 
regression 2.19 (1.18–3.39) 0.01
Age, gender, BMI, HCV 
G3, diabetes, alcohol 
intake, ancestry, PNPLA3 
I148M
None Fibrosis Ishak25 EK + KK: 0/9/18/10/9/2/21 F(X + 1) vs. F(X)e Ordinal regression 1.23 (0.99–1.53) 0.06
Age, gender, BMI, HCV 
G3, diabetes, alcohol 
intake, ancestry, PNPLA3 
I148M
M. Milano, 2015, validation 
cohort20 None Fibrosis METAVIR
27 NA F2-F4 vs. F0-F1 Logistic regression 1.81 (1.02–3.04) 0.02 Age and gender
S. Petta, 201522 None Steatosis NAS24 S0/S1/S2: EE:356/187/107 EK + KK:21/14/9 S(X + 1) vs. S(X)
Ordinal 
regression 1.48 (0.82–2.69) 0.19
Age, gender, BMI, 
HOMA-IR
None Inflamma tion Scheuer26 G4/G0 + G1 + G2 + G3: EE: 285/365 EK + KK: 17/27 G4 vs. G0-G3 Chi-square 0.81 (0.43–1.51) 0.50 None
None Fibrosis Scheuer26 F0-F2/F3-F4: EE:449/201 EK + KK:33/11 F3-F4 vs. F0-F2
Logistic 
regression 0.75 (0.34–1.63) 0.47
Age, gender, BMI, 
HOMA-IR, PNPLA3 
I148M, and IL-28B 
rs12979860
M. Eslam, 201621 None Steatosis NAS24 S0/S1/S2/S3 EE:922/533/237/86 EK:100/94/22/19 KK:2/4/3/1 S2 + S3 vs. S0 + S1
Logistic 
regression 1.14 (1.02–1.27) 0.01
Age, gender, BMI, 
HOMA-IR, HCV 
genotype, alcohol intake, 
and PNPLA3 I148M
Genotype3 
CHC Steatosis NAS
24 NA S(X + 1) vs. S(X) Ordinal regression 1.05 (0.99–1.08) 0.50
Age, gender, BMI, 
HOMA-IR, and PNPLA3 
I148M
Genotype 
(1 + 2 + 4) 
CHC
Steatosis NAS24 NA S(X + 1) vs. S(X) Ordinal regression 1.12 (1.11–1.13) 0.04
Age, gender, BMI, 
HOMA-IR, and PNPLA3 
I148M
None Inflamma tion METAVIR27 G0/G1/G2/G3 EE:75/889/620/194 EK:11/129/74/21 KK:1/1/6/2 G(X + 1) vs. G(X)
Ordinal 
regression 1.04 (0.85–1.26) 0.10
Age, gender, steatosis, 
HOMA-IR, BMI, HCV 
genotype,alcohol intake, 
and PNPLA3 I148M
None Fibrosis METAVIR27
F0/F1/F2/F3/F4 
EE:232/630/512/248 /156 
EK:36/87/60/22/30 KK:1/3/0/5/1
F2-F4 vs. F0-F1 Logistic regression 1.39 (1.04–1.87) 0.02
Age, gender, steatosis, 
HOMA-IR, BMI, HCV 
genotype, alcohol intake, 
and PNPLA3 I148M
F4 vs. F0-F3 Logistic regression 1.82 (1.01–3.28) 0.01
Age, gender, steatosis, 
HOMA-IR, BMI, HCV 
genotype, alcohol intake, 
and PNPLA3 I148M
F(X + 1) vs. F(X) Ordinal regression 1.07 (1.01–1.14) 0.04
Age, gender, steatosis, 
HOMA-IR, BMI, HCV 
genotype, alcohol intake, 
and PNPLA3 I148M
Table 2. Genetic impact of TM6SF2 E167K polymorphism on hepatic histological features in the selected 
studies. aS, G and F respectively represent the histological severity on steatosis, inflammation and fibrosis; 
bTM6SF2 E167K variant is coded in dominant genetic model (EE/EK + KK) for each comparison; cS(X + 1) 
vs.S(X) means the continuous comparison between subgroups with adjacent advanced and mild steatosis; 
dG(X + 1) vs.G(X) means the continuous comparison between subgroups with adjacent advanced and mild 
inflammation; eF(X + 1) vs.F(X) means the continuous comparison between subgroups with adjacent advanced 
and mild fibrosis.
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was based on only two data points with moderate heterogeneity (I2 = 25.5% and 49.3% for LDL-C and HDL-C in 
Fig. 5C and D, respectively).
Association of TM6SF2 variant with metabolic traits and viral load in patients with CHC. The 
impact of the TM6SF2 variant on glucose levels and insulin resistance were reported in three and two studies, 
respectively (Figure S7). Convincing evidence showed negative results for the comparison between carriers with 
the TM6SF2 variant on fasting glucose value (5.23 ± 0.81 vs. 5.30 ± 1.47 mmol/L, pooled SMD = −0.05, 95% 
CI = −0.17/0.07 mmol/L) and HOMA-IR (2.48 ± 3.26 vs. 2.45 ± 4.66, pooled SMD = 0.02, 95% CI = −0.10/0.15, 
both I2 = 0%).
The TM6SF2 variant was associated with lower BMI (i.e., carriers of the E167K mutation tended to be leaner; 
Figure S8), but with high heterogeneity (I2 = 97.2%). However, after excluding the study by Coppola et al., which 
had a smaller sample size and inferior study quality, carriage of the E167K variant was associated with a 2% 
decrease in BMI (25.6 ± 3.9 vs. 26.1 ± 4.4 kg/m2; pooled SMD = 0.15, 95% CI = 0.04–0.26 kg/m2; data not shown) 
in the absence of obvious heterogeneity (I2 = 0%).
All four studies compared the HCV-RNA load in subgroups stratified by the TM6SF2 genotype (Figure S9). 
HCV-RNA levels did not differ in carriers with the E167K variant vs. non-carriers (5.70 ± 1.62 vs. 5.77 ± 1.57; 
quantitative HCV RNA after log transformation). However, a moderate to high inconsistency was observed 
(I2 = 58.9%).
Phenotype-disease association based on the Mendelian randomization analysis. TGs and TC 
were selected as candidate phenotypes for the Mendelian randomization (MR) analysis of the for stable associ-
ation with TM6SF2 variant in high consistence (I2 < 25%). As Figure S10 shows, we found approximately 52% 
(OR = 0.48, 95% CI: 0.33–0.68) and 58% (OR = 0.42, 95% CI: 0.29–0.65) decreases in the risk of more severe 
steatosis per 1 mmol/L increase in circulating TG and TC levels, respectively. However, the causal effect of TG or 
TC variation was nonsignificant in patients with advanced fibrosis stages (the 95% CI of ORphenotype-disease ranged 
across 1; Figure S10).
Publication bias analysis. Begg’s funnel plot was applied to examine publication bias (Figure S11). 
Although a slight asymmetry was observed in this plot (Figure S11A), no significant publication bias was detected 
using either Egger’s or Begg’s tests (P > 0.05).
Discussion
The current study performed a systematic review and meta-analysis of the literature concerning the effect of the 
TM6SF2 E167K variant on liver disease severity in patients with CHC, while also addressing its influence on 
metabolic and viral features. The major finding are that the TM6SF2 E167K variant favors the development of ste-
atosis and fibrosis, but not of inflammation, in individuals with CHC infection. In our analyses, E167K was asso-
ciated more robustly with fibrosis than with steatosis. This result might be related to known higher inter-observer 
variability in the classification of steatosis than fibrosis that is consistently reported across studies28, as well as to 
the well-established steatogenic effect of infection via HCV-G329. Alternatively, the measurement of hepatic intra-
cellular lipid content via histology might underestimate the disturbance in lipid handling among patients with 
advanced liver fibrosis because of the reduction in hepatic lipid accumulation with progressive accumulation of 
extracellular matrix in the liver30.
Importantly, carriage of the TM6SF2 E167K variant conferred a stable and significant predisposition towards 
the development of progressive hepatic fibrosis. In particular, our pooled results found that the TM6SF2 variant 
predicted the risk of cirrhosis. Overall, the results of the present analysis suggest that carriage of the E167K 
TM6SF2 variant predicts an increased risk of clinically significant and advanced fibrosis in patients with CHC. 
The same conclusion might be drawn for the presence of steatosis in general because histological steatosis is asso-
ciated with faster fibrosis progression independent of its aetiology31, and other genetic determinants of hepatic 
fat content, (e.g., the PNPLA3 I148M and MBOAT7 variation) are associated with fibrosis development patients 
with CHC8, 10, 32. Because the impact of E167K TM6SF2 on fibrosis progression is not restricted to patients with 
CHC16, 17, 33, and carriers of the variant have more advanced fibrosis at diagnosis on average, future studies should 
determine whether this genetic factor can be used to predict the risk of liver-related complications after viral 
eradication.
Furthermore, the TM6SF2 variant was associated with lower circulating serum lipids, primarily on TGs and 
non-HDL cholesterol. This finding is consistent with the model in which the TM6SF2 variant favours steatosis 
development because of decreased VLDL secretion and lipidation12–14, 34, 35. Using an MR analysis as an integrated 
approach across genotypes, phenotypes, and histological features, we found that the genetic susceptibility conferred 
by the TM6SF2 variant on steatosis (but not fibrosis) severity was influenced by lipid phenotypes with regard to 
their causal effects on lipid accumulation in patients with CHC. In fact, 1 unit (mmol/L) of decrease in TG/TC level 
might increase the susceptibility of steatosis approximately 2-folds. Importantly, the TM6SF2 variation showed a 
common but distinguished impact on steatosis both in patients with G3 and those with non-G3 HCV infection, 
suggesting that the TM6SF2 variant independently influences hepatic fat accumulation even in the presence of the 
strong viral factors that inhibit VLDL secretion via other mechanisms6, 36, 37. Therefore, the dissociation of the E167K 
variant between more severe liver damage but more favourable lipid profile observed in the general population and 
non-alcoholic fatty liver disease (NAFLD) patients is also present in patients with CHC.
The association between the TM6SF2 genotype and liver damage was not confounded by metabolic cofactors. 
Indeed, in keeping with observations of the general population12, 22 and patients with NAFLD16, 34, the E167K 
variant was not associated with an increased risk of hyperglycaemia or insulin resistance. Intriguingly, the current 
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summary of the available evidence revealed an association between carriage of the TM6SF2 E167K variant and 
slightly reduced BMI. Although it is tempting to speculate that the association might depend on impairments in 
chylomicrons and VLDL secretion (thereby supporting adipose tissue growth in carriers of the mutation), we 
must remember that the E167K variant does not affect BMI in the general population12. Conversely, the E167K 
variant was associated with an increased risk of cirrhosis, an important cause of malnutrition and low BMI, which 
might have driven the observed association38. Additional epidemiological investigations evaluating single patient 
data are required to confirm this association.
One important difference between the results of the present analysis and findings derived from studies con-
ducted in patients with NAFLD16 is that the TM6SF2 variation was not associated with histological hepatic 
inflammation in CHC. This is possibly due to interference of the E167K variant in the process of VLDL secre-
tion that impairs HCV viremia and infectivity39. This hypothesis is also supported by the evidence collected in 
genetic studies of individuals with NAFLD, in whom genetic susceptibility to hepatic lipid accumulation is the 
major determinant of liver damage progression40, 41. One important caveat to note is that steatosis and TM6SF2 
variation increase the risk of lobular necroinflammation with the infiltration of granulocytes34, a typical feature 
of non-alcoholic steatohepatitis24. Conversely, histological scores developed for CHC primarily capture the portal 
and peri-portal infiltration of lymphocytes, and can miss the nonalcoholic steatohepatitis (NASH)-related fea-
tures of liver damage possibly associated with TM6SF2 variation. Nevertheless, our findings reinforce the notion 
that circulating aminotransferase levels, which are not affected by TM6SF2 variation in patients with CHC23, are 
not an accurate predictor of the severity of damage and fibrosis.
Group
Steatosis Fibrosis
Data 
points 
(n)
Pooled ORa 
(95% CI) P1c P2d
Data 
points (n)
Pooled ORb (95% 
CI) P1 P2
Mean age(yr)
  ≤50 1 1.14 (1.02–1.27) NA 1 1.39 (1.04–1.87) NA
  >50 3 1.80 (1.18–2.74) 0.347 0.041 4 1.29 (0.94–1.78) 0.339 0.745
Gender
  Women% <40% 1 1.14 (1.02–1.27) NA 1 1.39 (1.04–1.86) NA
  Women% >40% 3 1.80 (1.18–2.74) 0.347 0.041 4 1.29 (0.94–1.78) 0.339 0.745
Mean BMI(kg/m2)
  ≤26 2 2.07 (1.24-3.43) 0.281 2 1.23 (0.79–1.93) 0.953
  >26 2 1.14 (1.03–1.27) 0.723 0.025 2 1.29 (0.98–1.70) 0.148 0.869
Sample size(n)
  ≤1000 3 1.80 (1.18-2.74) 0.347 4 1.29 (0.94–1.78) 0.339
  >1000 1 1.14 (1.02–1.27) NA 0.041 1 1.39 (1.04–1.86) NA 0.745
Naïve for antiviral therapy
  Yes 3 1.17 (1.05–1.30) 0.045 4 1.41 (1.13–1.77) 0.763
  No 1 1.31 (0.61–2.80) NA 0.774 1 0.75 (0.34–1.64) NA 0.129
Prevalence of G3 CHC(%)
  ≤10% 2 1.60 (1.01–2.52) 0.520 2 1.07 (0.70–1.64) 0.290
  >10% 2 1.15 (1.03–1.29) 0.046 0.171 2 1.37 (1.04–1.82) 0.782 0.337
Prevalence of EK + KK carriers(%)
  ≤10% 2 1.60 (1.01-2.52) 0.520 2 1.07 (0.70–1.64) 0.290
  >10% 2 1.15 (1.03–1.29) 0.046 0.171 3 1.46 (1.13–1.87) 0.654 0.222
Adjustment of PNPLA3 I148M
  No 2 1.80 (0.96–3.37) 0.146 3 1.44 (1.02–2.04) 0.567
  Yes 2 1.16 (1.04–1.29) 0.128 0.174 2 1.29 (0.98–1.70) 0.148 0.623
Adjustment of steatosis presence
  No 4 1.29 (0.94–1.78) 0.339
  Yes 1 1.39 (1.04–1.87) NA 0.745
Scoring systeme
  Ishak25 2 1.23 (0.79–1.93) 0.953
  METAVIR27 2 1.47 (1.14–1.91) 0.404
  Scheuer26 1 0.75 (0.34–1.64) NA 0.251
Table 3. Subgroup analysis on genetic association among TM6SF2 E167K polymorphism and histological 
features in chronic hepatitis C patients. aOR represents the risk of significant steatosis for EK + KK carriage 
compared to EE group; bOR represents the risk of significant fibrosis for EK + KK carriage compared to 
EE group; cP1 represents the heterogeneity of pooled result within each subgroup; dP2 represents the inter-
subgroup heterogeneity across studies categorized by the same criteria; eComparison was only applied for 
fibrosis because no difference observed in criteria defining the steatosis severity.
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The limitations of our findings include the following. First, the main results were pooled from only four 
papers based on participants of European-descent selected using strict criteria; however, the completion of a 
meta-analysis on the impact of the TM6SF2 variant on hepatic damage and the assessment of potential contro-
versies across studies containing patients with CHC is noteworthy. Second, attention should be focused on the 
lack of stability of the pooled results for different scoring systems applied across studies (Table S3). Third, we 
chose aggregate data (AD) in the enrolled literature with clinical and statistical inferiority to individual partic-
ipant data (IPD). In our case, however, the OR was calculated based on the raw data provided in original tables 
and histograms from the literature, which are considered equivalent to an IPD meta-analysis42. Nevertheless, 
IPD meta-analyses of studies, are still needed to reach even more reliable conclusions less subjected to potential 
bias. Fourth, a lack of adjustment for steatogenic factors such as alcohol intake and less consistent data clusters in 
the subgroup analysis might have biased the pooled results. Finally, despite the uneven distribution of TM6SF2 
genotypes across patients infected by diverse HCV genotypes (Figure S1), we were unable to evaluate the impact 
of TM6SF2 variation on fibrosis development in subgroups stratified by HCV genotypes because of the lack of 
available information.
In conclusion, by systematically reviewing and meta-analysing the available literature, we found that the 
TM6SF2 E167K variant is associated with an increased predisposition towards the development of the full spec-
trum of steatosis and fibrosis (but not inflammation) in individuals of European descent with CHC infection. This 
variant is associated with a reduction in circulating non-HDL cholesterol and TG levels. Decreased TC and TG 
levels might amplify the genetic susceptibility of TM6SF2 variant on advanced steatosis.
Figure 3. Forest plot of genetic association for TM6SF2 E167K polymorphism on inflammation status 
in chronic hepatitis C patients. Pooled dichotomous odds ratio of TM6SF2 E167K variant (EK + KK) on 
severe inflammationa compared to non-severe inflammation group in chronic hepatitis C patients. aSevere 
inflammation was defined as G13-G18 status in study applying Ishak criteria25 and G4 status in study applying 
Scheuer26 and METAVIR27 criteria.
Figure 2. Forest plot of genetic association for TM6SF2 E167K polymorphism on steatosis status in chronic 
hepatitis C patients. (A) Pooled continuous odds ratio of TM6SF2 E167K variant (EK + KK) on steatosis 
severity in patients categorized by hepatitis C virus genotypes; (B) Pooled dichotomous odds ratio for TM6SF2 
E167K variant (EK + KK) on significant steatosis (≥S2) compared to non-significant steatosis group (<S2) in 
chronic hepatitis C patients.
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Experimental Procedures
Literature retrieval and selection. A comprehensive search for literature addressing the genetic associ-
ations of TM6SF2 variants on hepatic steatosis and relevant complications in patients with CHC was conducted 
using the Medline, EMBASE, and the Cochrane Library databases without language restriction (updated until 
May 20, 2017). Additionally, we manually searched for “grey” literature on website (e.g., the BIOSIS, EAGLE, 
and INIST databases) according to the guidance of the Cochrane Handbook for Systematic Reviews (Version 
5.1.0, http://handbook.cochrane.org/front_page.htm). The reference lists of enrolled studies and publications 
with citations of included papers were also reviewed for suitable papers. Our literature search strategy is shown 
Figure 4. Forest plot of genetic association for TM6SF2 E167K polymorphism on fibrosis status in chronic 
hepatitis C patients. (A) Pooled continuous odds ratio of TM6SF2 E167K variant (EK + KK) on advanced 
fibrosis severity in chronic hepatitis C patients; (B) Pooled dichotomous odds ratio for TM6SF2 E167K variant 
(EK + KK) on significant fibrosisa compared to non-significant fibrosis group in chronic hepatitis C patients. 
aSignificant fibrosis was defined as ≥ F3 in studies applying for Ishak criteria25, and ≥ F2 in studies applying for 
METAVIR criteria27.
Figure 5. Forest plot for genetic impact of TM6SF2 E167K polymorphism on circulating lipids in chronic 
hepatitis C patients. (A) Pooled standardized mean differences of triglyceride level in subgroups with different 
TM6SF2 E167K polymorphism (EK + KK vs. EE); (B) Pooled standardized mean differences of total cholesterol 
level in subgroups with different TM6SF2 E167K polymorphism (EK + KK vs. EE); (C) Pooled standardized 
mean differences of low density lipoprotein cholesterol level in subgroups with different TM6SF2 E167K 
polymorphism (EK + KK vs. EE); (D) Pooled standardized mean differences of high density lipoprotein 
cholesterol level in subgroups with different TM6SF2 E167K polymorphism (EK + KK vs. EE).
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in Table S1. Relevant papers were initially selected after browsing title and abstract, and then two authors (ZT L 
and SP Q) reviewed the full text.
Qualified studies were selected when they met the following criteria: 1. Patients were clearly diagnosed with 
CHC but were free of other severe liver/systemic disease; 2. The TM6SF2 E167K variant was genotyped using 
reliable methods; 3. Histological features were assessed via liver biopsy under the guidance of a pre-defined scor-
ing system; 4. The risk of hazardous variants on the susceptibility of hepatic histological lesions was reported or 
could be calculated. If two (or more) studies included the same cohort, then the most recent study was included.
Data extraction. The following information provided by the enrolled studies was extracted: study name, 
population characteristics (e.g., ethnicity, gender, age, body mass index [BMI)), study design, HCV genotype 
distribution, and TM6SF2 genotyping (methods, number of carriers, and Hardy-Weinberg equilibrium P value). 
Then, additional information concerning the association between the TM6SF2 E167K polymorphism and specific 
histological features (categorised by steatosis, inflammation and fibrosis) including the scoring system, number of 
patients with different disease severities classified by TM6SF2 variants, comparisons, corresponding odds ratios 
(ORs), and adjusted covariates were also collected. In addition, quantitative indicators of lipids (triglycerides 
[TGs], total cholesterol [TC), low density lipoprotein cholesterol [LDL-C), high density lipoprotein cholesterol 
[HDL-C)), insulin resistance (fasting blood glucose, homeostatic model assessment insulin resistance index 
[HOMA-IR43]), and viral load of HCV RNA, categorised by TM6SF2 variants, were collected when available. 
The corresponding authors of the original studies were contacted via e-mail for data missing from the published 
papers when necessary.
Quality assessment. The qualities of the enrolled studies were systematically assessed using the 
pre-recommended criteria from Strengthening the Reporting of Genetic Association (STREGA) study guide-
lines44. Eleven items were included in the qualitative checklist (Table S2).
Statistical analysis. We adopted a dominant model (EK + KK vs. EE) to evaluate the genetic impacts, 
because of low prevalence of carriers with the homozygous variant (KK). Quantitative phenotypes that used dif-
ferent units across studies were unified before comparisons. For covariates reported in participants with CT and 
TT genotypes, the data were combined according to the number (N), mean and standard deviation (SD) using 
pre-defined formulas45.
If the original results were not reported, then data were extracted using Engauge Digitizer version 4.1 (http://
digitizer.sourceforge.net/). Reported medians and interquartile ranges were transformed to mean values and SDs 
according to pre-defined methods46. The OR (if not given) and deviation of genotype distribution taken from the 
Hardy-Weinberg equilibrium were tested using the chi-square test.
The difference in quantitative phenotypes was evaluated via the pooled standard mean difference (SMD) and 
corresponding 95% confidence intervals (CIs). With respect to the categorical variables, pooled ORs and 95% CIs 
were used to assess the genetic effects on disease predisposition. Pooled ORs and SMDs were calculated using 
Metan47. The continuous risks of TM6SF2 variation on the severity of the histological features were evaluated via 
the generalised least squares (GLST) method48. We separately calculated the pooled risk stratified by potential 
confounds to assess their impacts on the associations between the TM6SF2 variant and histological features. A 
cumulative meta-analysis was performed to identify the change in effect as the study sample sizes increased. A 
sensitivity analysis was performed by omitting one study sequentially to examine its effect on the overall results49. 
Publication bias was evaluated using Egger’s funnel plot and Begg’s test50.
The causal effects of the quantitative phenotypes on the genetic associations between the TM6SF2 E167K 
polymorphism and histological severity (primarily steatosis and fibrosis) were examined via a Mendelian ran-
domisation (MR) approach in absence of reverse causation and unadjusted confounds51, 52. In our study, expo-
sure indicators, which were more strongly correlated with the TM6SF2 variant in low heterogeneity (P < 0.05, 
I2 < 25%) were selected for the MR analysis. The risk associated with carrying the TM6SF2 variant on more severe 
steatosis/fibrosis was defined as OREK/KK vs. EE, and the mean difference on the quantitative phenotype was defined 
asΔP. ORphenotype-disease was calculated using OREK/KK vs. EE1/ΔP as a non-confounded effect with confounders on the 
risk of more severe steatosis/fibrosis per 1 unit of elevation on the candidate phenotype.
The heterogeneity caused by discrepancies across different studies was assessed using the I2 test. Thresholds 
of 25%, 50%, and 75% were considered as representing low, moderate, and high heterogeneities, respectively53. A 
fixed-effect model was used in the case of nonsignificant heterogeneity (P > 0.05, I2 < 50%), and a random-effects 
model was used for other conditions. All analysis was performed by STATA 12.0 (College station, TX, USA). 
P < 0.05 was considered significant.
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